Largest benefits seen for patients older than 60 years with no increased risk for hemorrhagic complications<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, March 30, 2022 (HealthDay News) — Early aspirin use is associated with lower odds of 28-day in-hospital mortality among U.S. adults hospitalized with moderate COVID-19, according to a study published online March 24 in JAMA Network Open<\/em>.<\/p>\n Jonathan H. Chow, M.D., from George Washington University in Washington, D.C., and colleagues examined associations between early aspirin use in hospitalized patients with moderate COVID-19 and odds of 28-day in-hospital mortality. The analysis included 112,269 hospitalized patients with moderate COVID-19 (Jan. 1, 2020, through Sept. 10, 2021) treated at 64 U.S. health systems.<\/p>\n The researchers found that 28-day in-hospital mortality was significantly lower in those who received aspirin (10.2 versus 11.8 percent; odds ratio [OR], 0.85). The rate of pulmonary embolism was also significantly lower in patients who received aspirin (1.0 versus 1.4 percent; OR, 0.71). In patients receiving aspirin, the composite of hemorrhagic complications did not occur more often (3.7 percent aspirin versus 3.2 percent no aspirin; OR, 1.13). Patients older than 60 years (61 to 80 years: OR, 0.79; older than 80 years: OR, 0.79) and patients with comorbidities (one comorbidity: OR, 0.68; two comorbidities: OR, 0.80; three comorbidities: OR, 0.78; more than three comorbidities: OR, 0.74) showed the most benefit.<\/p>\n “These findings warrant further study in a randomized clinical trial that includes diverse patients with cardiovascular comorbidities,” the authors write.<\/p>\n Several authors disclosed financial ties to pharmaceutical and medical companies. <\/p>\n